News

Sean Parker’s I/O group teams up with CRI for cancer neoantigens R&D deal

December 1, 2016

Sean Parker’s I/O group teams up with CRI for cancer neoantigens R&D deal

FierceBiotech

by Ben Adams

Facebook and Napster billionaire Sean Parker has seen his Institute for Cancer Immunotherapy join forces with the Cancer Research Institute (CRI) to work on boosting personalized medicine.

The new collab is specifically focused on neoantigens, a type of therapy that is a burgeoning field in cancer research right now, with many seeking to develop personalized therapeutic cancer vaccines that use unique neoantigens—antigens which are foreign to the body, found in cancer—that can be used to spur a specific immune system attack tailored to the individual patient.

Read Full Article